Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.5 Billion KRW | 1295.22% |
| 2022 | 251.47 Million KRW | -97.17% |
| 2021 | 8.89 Billion KRW | -54.99% |
| 2020 | 19.76 Billion KRW | 3.08% |
| 2019 | 19.17 Billion KRW | 481.02% |
| 2018 | 3.3 Billion KRW | -43.23% |
| 2017 | 5.81 Billion KRW | 186.93% |
| 2016 | 2.02 Billion KRW | 128.63% |
| 2015 | -7.07 Billion KRW | 44.09% |
| 2014 | -12.65 Billion KRW | 41.12% |
| 2013 | -21.49 Billion KRW | -635.61% |
| 2012 | -2.92 Billion KRW | 79.88% |
| 2011 | -14.52 Billion KRW | -6898.56% |
| 2010 | 213.65 Million KRW | -63.29% |
| 2009 | 581.95 Million KRW | -50.26% |
| 2008 | 1.17 Billion KRW | 213.63% |
| 2007 | -1.02 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -323 Million KRW | 88.72% |
| 2024 Q2 | -3.32 Billion KRW | -929.1% |
| 2024 Q3 | 222 Million KRW | 106.68% |
| 2023 Q3 | 318.81 Million KRW | -95.64% |
| 2023 Q4 | -2.86 Billion KRW | -998.06% |
| 2023 Q2 | 7.3 Billion KRW | 682.86% |
| 2023 Q1 | -1.25 Billion KRW | -288.25% |
| 2023 FY | 3.5 Billion KRW | 1295.22% |
| 2022 Q1 | -82.77 Million KRW | 91.29% |
| 2022 Q3 | 1.49 Billion KRW | 2029.79% |
| 2022 Q4 | -322.87 Million KRW | -121.66% |
| 2022 FY | 251.47 Million KRW | -97.17% |
| 2022 Q2 | -77.24 Million KRW | 6.68% |
| 2021 Q1 | 4.52 Billion KRW | -27.9% |
| 2021 Q3 | 2.05 Billion KRW | -36.84% |
| 2021 Q4 | -950.34 Million KRW | -146.14% |
| 2021 Q2 | 3.26 Billion KRW | -27.94% |
| 2021 FY | 8.89 Billion KRW | -54.99% |
| 2020 FY | 19.76 Billion KRW | 3.08% |
| 2020 Q2 | 5.89 Billion KRW | 52.1% |
| 2020 Q3 | 3.71 Billion KRW | -37.02% |
| 2020 Q1 | 3.87 Billion KRW | -37.74% |
| 2020 Q4 | 6.27 Billion KRW | 69.01% |
| 2019 FY | 19.17 Billion KRW | 481.02% |
| 2019 Q2 | 4.19 Billion KRW | 27.09% |
| 2019 Q3 | 5.45 Billion KRW | 30.17% |
| 2019 Q4 | 6.22 Billion KRW | 14.1% |
| 2019 Q1 | 3.29 Billion KRW | 223.62% |
| 2018 Q2 | 2.7 Billion KRW | 276.64% |
| 2018 FY | 3.3 Billion KRW | -43.23% |
| 2018 Q4 | -2.66 Billion KRW | -204.63% |
| 2018 Q3 | 2.55 Billion KRW | -5.59% |
| 2018 Q1 | 717.15 Million KRW | -76.35% |
| 2017 Q1 | -414.59 Million KRW | 28.91% |
| 2017 Q4 | 3.03 Billion KRW | 12.34% |
| 2017 FY | 5.81 Billion KRW | 186.93% |
| 2017 Q2 | 496.88 Million KRW | 219.85% |
| 2017 Q3 | 2.69 Billion KRW | 443.17% |
| 2016 Q4 | -583.15 Million KRW | -11.63% |
| 2016 FY | 2.02 Billion KRW | 128.63% |
| 2016 Q1 | 1.7 Billion KRW | 136.23% |
| 2016 Q2 | 1.42 Billion KRW | -16.06% |
| 2016 Q3 | -522.4 Million KRW | -136.56% |
| 2015 Q4 | -4.69 Billion KRW | -76.51% |
| 2015 Q2 | -35.87 Million KRW | -111.17% |
| 2015 Q3 | -2.66 Billion KRW | -7322.03% |
| 2015 Q1 | 321.09 Million KRW | 102.35% |
| 2015 FY | -7.07 Billion KRW | 44.09% |
| 2014 Q3 | 243.95 Million KRW | 0.96% |
| 2014 FY | -12.65 Billion KRW | 41.12% |
| 2014 Q1 | 528.33 Million KRW | 104.16% |
| 2014 Q4 | -13.67 Billion KRW | -5704.29% |
| 2014 Q2 | 241.62 Million KRW | -54.27% |
| 2013 FY | -21.49 Billion KRW | -635.61% |
| 2013 Q4 | -12.7 Billion KRW | -144.58% |
| 2013 Q3 | -5.19 Billion KRW | -226.76% |
| 2013 Q2 | -1.59 Billion KRW | 20.69% |
| 2013 Q1 | -2 Billion KRW | -69.0% |
| 2012 Q2 | -1.79 Billion KRW | -246.42% |
| 2012 FY | -2.92 Billion KRW | 79.88% |
| 2012 Q4 | -1.18 Billion KRW | -303.88% |
| 2012 Q3 | 581.88 Million KRW | 132.35% |
| 2012 Q1 | -519.27 Million KRW | 0.0% |
| 2011 Q2 | -6.25 Billion KRW | -2399.41% |
| 2011 FY | -14.52 Billion KRW | -6898.56% |
| 2011 Q1 | 272.2 Million KRW | 361.19% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 Q3 | -2.46 Billion KRW | 60.55% |
| 2010 Q1 | 71.46 Million KRW | -84.21% |
| 2010 FY | 213.65 Million KRW | -63.29% |
| 2010 Q4 | 59.02 Million KRW | 2.26% |
| 2010 Q3 | 57.71 Million KRW | 126.63% |
| 2010 Q2 | 25.46 Million KRW | -64.36% |
| 2009 Q2 | 81.86 Million KRW | 565.92% |
| 2009 Q1 | 12.29 Million KRW | -97.99% |
| 2009 Q3 | 35.15 Million KRW | -57.07% |
| 2009 Q4 | 452.64 Million KRW | 1187.74% |
| 2009 FY | 581.95 Million KRW | -50.26% |
| 2008 Q3 | 4.09 Million KRW | 101.0% |
| 2008 Q4 | 612.73 Million KRW | 14866.54% |
| 2008 FY | 1.17 Billion KRW | 213.63% |
| 2008 Q1 | 962.79 Million KRW | 35.59% |
| 2008 Q2 | -409.59 Million KRW | -142.54% |
| 2007 FY | -1.02 Billion KRW | 0.0% |
| 2007 Q2 | -55.3 Million KRW | 94.93% |
| 2007 Q3 | -593.47 Million KRW | -973.17% |
| 2007 Q1 | -1.09 Billion KRW | 0.0% |
| 2007 Q4 | 710.05 Million KRW | 219.64% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 148.86% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 93.95% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 105.888% |
| HANDOK Inc. | -28.79 Billion KRW | 112.184% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 141.694% |
| Yuhan Corporation | 93.5 Billion KRW | 96.248% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 68.455% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 114.141% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 97.601% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 239.985% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 269.178% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 177.541% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 84.289% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 148.86% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 116.755% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 2.086% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 102.967% |
| JW Holdings Corporation | 19.02 Billion KRW | 81.559% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 104.445% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 98.349% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.519% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 106.121% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 42.686% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -110.912% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 29.894% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 148.86% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 90.508% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 96.853% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.519% |
| Yuhan Corporation | 93.5 Billion KRW | 96.248% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 121.592% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 190.532% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 42.663% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.519% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 81.442% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 92.73% |
| CKD Bio Corp. | -24.19 Billion KRW | 114.503% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 85.33% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 87.213% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 88.216% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 106.121% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 92.536% |
| Boryung Corporation | 40.2 Billion KRW | 91.273% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 111.199% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 239.985% |
| JW Lifescience Corporation | 28.14 Billion KRW | 87.533% |